%0 Journal Article %T Effects of acetazolamide on linear growth in children with pseudotumor cerebri syndrome. %A Sheldon CA %A Reggie SN %A Paley GL %A McCormack SE %A Liu GT %J Front Ophthalmol (Lausanne) %V 2 %N 0 %D 2022 %M 38983548 暂无%R 10.3389/fopht.2022.1042529 %X UNASSIGNED: While oral acetazolamide is a cornerstone of management of adult and pediatric PTCS, previous studies have suggested that acetazolamide used in children with other conditions may influence growth.
UNASSIGNED: Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available before and during acetazolamide treatment (n=22).
UNASSIGNED: Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.
UNASSIGNED: Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.